Circulating tumor DNA (ctDNA) has emerged as an innovative and minimally invasive tool in precision oncology. With a short half-life of 30–120 min, ctDNA provides real-time insight into tumor dynamics.1 In early-stage breast cancer, there is growing evidence supporting its potential for minimal residual disease (MRD) detection and recurrence monitoring. In metastatic breast cancer (MBC), ctDNA […]
Advertisement
touchONCOLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Save your progress for video
Keep track of your CME credits
Add personalised learning notes
Receive updates from course leaders and faculty
Be the first to hear about new and exciting interactive learning opportunities
Register Register
Login
Login
Sign Up FREE
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Register now for FREE Access
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.